Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Gautschi

Showing results (31-40 of 91) with videos related to

Pageof 10
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2016
Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)Sabine Schmid, Oliver Gautschi, Sacha Rothschild, et al.
Clinical Lung Cancer|March 27, 2007
Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategiesDavid R Gandara, Angela M Davies, Oliver Gautschi, et al.
BMC Medical Imaging|July 12, 2017
The value of ultrasound-guided biopsy of fluorodeoxy-glucose positron emission tomography (FDG-PET)-positive supraclavicular lymph nodes in patients with suspected lung cancerLennart Werner, Franziska Aebersold Keller, Ujwal Bhure, et al.
Lung Cancer (Amsterdam, Netherlands)|January 13, 2006
Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patientsOliver Gautschi, Barbara Hugli, Annemarie Ziegler, et al.
Lung Cancer (Amsterdam, Netherlands)|May 22, 2007
Low prevalence of SV40 in Swiss mesothelioma patients after elimination of false-positive PCR resultsAnnemarie Ziegler, Christian A Seemayer, Marc Hinterberger, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 15, 2018
A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC)Cedric M Panje, Konstantin J Dedes, Klazien Matter-Walstra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2004
Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapyOliver Gautschi, Colette Bigosch, Barbara Huegli, et al.
Plos One|September 17, 2013
EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancerFlorent Baty, Sacha Rothschild, Martin Früh, et al.
Journal for Immunotherapy of Cancer|May 24, 2018
Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse eventsHeinz Läubli, Catharina Balmelli, Lukas Kaufmann, et al.
Frontiers in Oncology|September 25, 2020
Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer PatientsChristian Britschgi, Alfredo Addeo, Markus Rechsteiner, et al.
Pageof 10

Showing results (31-40 of 91) with videos related to

Sort By:
Pageof 10
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2016
Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)Sabine Schmid, Oliver Gautschi, Sacha Rothschild, et al.
Clinical Lung Cancer|March 27, 2007
Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategiesDavid R Gandara, Angela M Davies, Oliver Gautschi, et al.
BMC Medical Imaging|July 12, 2017
The value of ultrasound-guided biopsy of fluorodeoxy-glucose positron emission tomography (FDG-PET)-positive supraclavicular lymph nodes in patients with suspected lung cancerLennart Werner, Franziska Aebersold Keller, Ujwal Bhure, et al.
Lung Cancer (Amsterdam, Netherlands)|January 13, 2006
Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patientsOliver Gautschi, Barbara Hugli, Annemarie Ziegler, et al.
Lung Cancer (Amsterdam, Netherlands)|May 22, 2007
Low prevalence of SV40 in Swiss mesothelioma patients after elimination of false-positive PCR resultsAnnemarie Ziegler, Christian A Seemayer, Marc Hinterberger, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 15, 2018
A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC)Cedric M Panje, Konstantin J Dedes, Klazien Matter-Walstra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2004
Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapyOliver Gautschi, Colette Bigosch, Barbara Huegli, et al.
Plos One|September 17, 2013
EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancerFlorent Baty, Sacha Rothschild, Martin Früh, et al.
Journal for Immunotherapy of Cancer|May 24, 2018
Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse eventsHeinz Läubli, Catharina Balmelli, Lukas Kaufmann, et al.
Frontiers in Oncology|September 25, 2020
Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer PatientsChristian Britschgi, Alfredo Addeo, Markus Rechsteiner, et al.
Pageof 10